Trial Profile
Efficacy and safety of Apatinib and Icotinib as first line therapy for EGFR co-mutations in non small cell lung cancer Chinese patients
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2018
Price :
$35
*
At a glance
- Drugs Icotinib (Primary) ; Rivoceranib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 10 Oct 2018 New trial record